Bovine herpes virus-1 compositions, vaccines and methods
View Patent ↗The disclosure relates generally to the treatment or prevention of disease in cattle. More particularly, the invention is directed to the production and use of modified bovine herpesvirus 1 (BHV-1) and their use in compositions and vaccines that protect cattle from BHV-1 infection while not suppressing the immunological response in the host. In one example, the invention is directed to the use of modified BHV-1, administered with additional immunogens, either through co-administration and/or through administration in combination vaccines, and the use of these vaccines for the protection of cattle from disease. In one example, use of the modified BHV-1 in the administered compositions facilitates an immune response to or against the additional immunogens.
1. A composition, comprising:
a) a live BHV-1 that has modifications of UL49.5 and at least one additional gene encoding protein that can affect a host immunological response to an immunogen; and
b) an additional immunogen which is not encoded by a foreign gene inserted in the genome of the live BHV-1,
where following administration of the composition to a host, a ratio of IgG1/IgG2 for IgG specific for the additional immunogen in the host is higher than a ratio of IgG1/IgG2 for IgG specific for the additional immunogen in a host administered a composition of live BHV-1 that does not have the modifications and the additional immunogen.
2. The composition of claim 1 , where the at least one additional gene is UL41 or Us4.
3. The composition of claim 1 , where following administration of the composition of live BHV-1 that has the modifications and the additional immunogen to the host, cell samples obtained from blood of the host and contacted with the additional immunogen have higher levels of interleukin-2 (IL-2) as compared to levels of IL-2 from cell samples obtained from blood of the host administered the composition of live BHV-1 that does not have the modifications and the additional immunogen, and contacted with the additional immunogen.
4. The composition of claim 3 , where the at least one additional gene is UL41.
5. The composition of claim 1 , where the additional immunogen includes a bacterial, viral or parasitic immunogen.
6. The composition of claim 1 , where the additional immunogen includes an immunogen from Bovine Viral Diarrhea Virus (BVDV) I, BVDV II, BVDV III, Bovine Respiratory Syncytial Virus (BRSV), Parainfluenza 3 Virus (PI3), Rotavirus (BRV), Coronavirus (BCV), Mannheimia haemolytica, Histophilus somni, Mycoplasma bovis, Leptospira species, Vibrio species, Clostridia species, Pasteurella multocida, Fusobacterium necrophorum, E. coli O157:H7, Salmonella enterica, Neospora caninum or Trichomonas species.
7. The composition of claim 1 , where the additional immunogen includes LkT from Mannheimia haemolytica.
8. A method for eliciting an immunological response in a host, comprising administering to the host a composition including:
a) an immunogen other than a BHV-1 antigen (non-BHV-1 immunogen), which is not encoded by a foreign gene inserted in a BHV-1 genome; and
b) a live BHV-1 that has modifications of UL49.5 and at least one additional gene encoding protein that can affect a host immunological response to an immunogen,
where following administration of the composition to the host, a ratio of IgG1 to IgG2 in the host for IgG specific for the non-BHV-1 immunogen is higher than a ratio of IgG1 to IgG2 for IgG specific for the non-BHV-1 immunogen in a host administered a composition of the non-BHV-1 immunogen and live BHV-1 that does not have the modifications.
9. The method of claim 8 , where the non-BHV-1 immunogen and the live BHV-1 are co-administered or administered to the host in a combination vaccine.
10. The method of claim 8 , where the at least one additional gene is UL41 or Us4.
11. The method of claim 8 , where following administration of the composition of non-BHV-1 immunogen and live BHV-1 that has the modifications to the host, cell samples obtained from blood of the host and contacted with the non-BHV-1 immunogen have higher levels of interleukin-2 (IL-2) as compared to levels of IL-2 from cell samples obtained from blood of the host administered the composition of the non-BHV-1 immunogen and live BHV-1 that does not have the modifications, and contacted with the non-BHV-1 immunogen.
12. The method of claim 11 , where the at least one additional gene is UL41.
13. The method of claim 8 , wherein the host is an ungulate.